{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Cyclacel Pharmaceuticals, Inc. overvalued or undervalued?
As of November 14, 2016, Cyclacel Pharmaceuticals is considered overvalued due to poor financial metrics, including a price-to-book ratio of 2.69 and an ROE of -272.53%, alongside significant underperformance against the S&P 500 with a year-to-date return of -94.56%.
Who are in the management team of Cyclacel Pharmaceuticals, Inc.?
As of March 2022, the management team of Cyclacel Pharmaceuticals, Inc. includes Dr. David U'Prichard (Independent Chairman), Spiro Rombotis (CEO), and several directors, including Dr. Christopher Henney (Independent Vice Chairman) and Paul McBarron (CFO). The team features a blend of executive leaders and independent directors for diverse governance.
What does Cyclacel Pharmaceuticals, Inc. do?
Cyclacel Pharmaceuticals, Inc. develops anticancer drugs based on cell cycle biology and has a market cap of $7.80 million. The company reported no net profit recently and has a dividend yield of 24.30%.
How big is Cyclacel Pharmaceuticals, Inc.?
As of Jun 18, Cyclacel Pharmaceuticals, Inc. has a market capitalization of 7.80 million, with net sales of 0.01 million and a net profit of -8.35 million over the last four quarters. The company reported shareholder's funds of -2.17 million and total assets of 4.09 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
